Table I.
Clinicopathological features and mutational pattern in 50 patients with thyroid carcinoma.
| Pathologic findings | Mutation | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Age/sex | Histology | Tumor size, cm | Stage | pT | pN | Extension | Multifocality | BRAF | PIK3CA | TP53 | Other |
| 1 | 61/F | PC | 2.0 | I | 1b | 0 | + | V600E | ||||
| 2 | 54/F | PC | 1.7 | I | 3b | 0 | + | V600E | ||||
| 3 | 65/F | PC | 1.6 | I | 3b | 0 | + | V600E | ||||
| 4 | 66/F | PC | 1.9 | I | 3b | 0 | + | V600E | ||||
| 5 | 69/F | PC | 2.4 | I | 3b | 0 | + | V600E | ||||
| 6 | 77/F | PC | 3.4 | I | 2 | 0 | V600E | |||||
| 7 | 36/F | PC | 1.9 | I | 4a | 1a | + | + | V600E | |||
| 8 | 75/F | PC | 2.5 | I | 2 | 0 | + | V600E | ||||
| 9 | 52/M | PC | 1.7 | I | 3b | 1a | + | + | V600E | |||
| 10 | 54/F | PC | 0.8 | I | 1a | 0 | + | V600E | ||||
| 11 | 56/F | PC | 2.5 | II | 3b | 1a | + | V600E | ||||
| 12 | 56/M | PC | 4.0 | II | 2 | 1a | V600E | |||||
| 13 | 72/F | PC | 0.7 | II | 3b | 0 | + | + | V600E | |||
| 14 | 67/F | PC | 2.3 | II | 3b | 1a | + | V600E | ||||
| 15 | 63/F | PC | 3.1 | II | 3b | 1b | + | + | V600E | |||
| 16 | 71/F | PC | 5.0 | II | 3b | 1b | + | + | V600E | |||
| 17 | 62/F | PC | 2.2 | II | 3b | 1a | + | V600E | ||||
| 18 | 55/F | PC | 1.6 | III | 4a | 1a | + | V600E | ||||
| 19 | 73/F | PC | 2.3 | III | 4a | 1a | + | V600E | ||||
| 20 | 73/F | PC | 2.3 | III | 4a | 0 | + | + | V600E | |||
| 21 | 80/F | PC | 2.1 | III | 4a | 1b | + | V600E | ||||
| 22 | 56/F | PC | 1.4 | III | 4a | 1b | + | + | V600E | |||
| 23 | 86/F | PC | 1.1 | III | 4a | 0 | + | V600E | ||||
| 24 | 77/F | PC | 2.7 | III | 4a | 0 | + | V600E | delPV104P | |||
| 25 | 77/F | PC | 3.2 | II | 3b | 1b | + | + | V600E | A1046T | R306* | FGFR3 (G382R) |
| 26 | 86/F | PC | 5.0 | IVB | 4b | 1b | + | + | C420R | EGFR (K852Q) | ||
| 27 | 49/F | PC | 5.9 | I | 4a | 1b | + | |||||
| 28 | 83/F | PC | 1.0 | III | 4a | 1b | + | |||||
| 29 | 78/F | PC | 1.1 | II | 3b | 0 | + | + | ||||
| 30 | 51/M | PC | 1.5 | I | 4a | 1b | + | + | ||||
| 31 | 26/F | TVPC | 0.8 | I | 3b | 1b | + | + | V600E | |||
| 32 | 83/F | TVPC | 4.5 | II | 3b | 1b | + | + | V600E | |||
| 33 | 85/F | FVPC | 4.4 | II | 3a | 0 | ||||||
| 34 | 56/F | FVPC | 1.7 | I | 1b | 0 | + | NRAS (Q61K) | ||||
| 35 | 49/F | FC | 3.2 | I | 2 | 0 | ||||||
| 36 | 76/F | FC | 3.6 | I | 2 | 0 | ||||||
| 37 | 71/F | FC | 1.0 | I | 1a | 0 | ||||||
| 38 | 56/F | FC | 3.4 | I | 2 | 0 | ||||||
| 39 | 55/F | FC | 7.5 | I | 1a | 0 | ||||||
| 40 | 54/F | FC | 3.6 | I | 2 | 0 | ||||||
| 41 | 74/F | FC | 6.5 | II | 3a | 0 | ||||||
| 42 | 71/M | FC | 4.6 | II | 3a | 0 | ||||||
| 43 | 76/F | PDC | 1.6 | II | 1b | 1a | + | V600E | ||||
| 44 | 81/F | PDC | 4.2 | IVB | 4a | 1b | + | + | V600E | |||
| 45 | 74/F | PDC | 1.4 | II | 1b | 1a | V600E | |||||
| 46 | 74/F | PDC | 2.0 | II | 3b | 0 | + | V600E | ||||
| 47 | 51/F | PDC | 2.5 | I | 4a | 1a | + | + | V600E | |||
| 48 | 28/M | PDC | 1.0 | I | 1a | 1b | + | V600E | H1047R | |||
| 49 | 67/F | PDC | 0.7 | II | 1a | 1a | + | |||||
| 50 | 86/F | AC | 0.6 | IVB | 1a | 1b | + | V600E | Q192* | |||
F, female; M, male; PC, papillary carcinoma; TVPC, papillary carcinoma tall cell variant; FVPC, papillary carcinoma follicular variant; FC, follicular carcinoma; PDC, poorly differentiated carcinoma; AC, anaplastic carcinoma; pT, pathological T stage; pN, pathological N stage.